Abstract
We investigated the effects of taxol, an antimicrotubule agent active in different cancers, on the human NCI-H295 steroid-secreting adrenocortical carcinoma cell line. Cells were incubated for 48, 72 or 96 h with taxol 10(-10)-10(-4) M. Cell viability was evaluated by MTT assay with IC50 calculation. Apoptosis was investigated by measuring DNA fragmentation with ELISA assay after cell exposure to taxol at IC50 for 24 h. For secretion studies, aldosterone, cortisol, testosterone and dehydroepiandrosterone-sulphate (DHEA-S) were measured by RIA in the conditioned medium after 96 h exposure to taxol 10(-10)-10(-6) M, and expressed as percentage of steroid production by control cells. By MTT, taxol induced a dose-dependent inhibition of cell proliferation, with ICs50 at 72-96 h corresponding to blood levels achieved in vivo in patients with other types of cancer. Nuclear fragmentation, morphologically confirmed at electron microscopy, showed a 4-fold increase after exposure to taxol. With 10(-6) M taxol, aldosterone decreased to 48%, cortisol to 61%, testosterone to 76% and DHEA-S to 89% of steroid production by control cells. Taxol is an effective cytotoxic and antiproliferative agent in a human adrenocortical steroid-secreting ca...Continue Reading
References
Nov 30, 1990·The Journal of Steroid Biochemistry and Molecular Biology·Y TakedaM Harnik
Apr 26, 1990·The New England Journal of Medicine·J P LutonP Blondeau
Aug 1, 1990·The Journal of Clinical Endocrinology and Metabolism·R V La RoccaC E Myers
Dec 16, 1983·Journal of Immunological Methods·T Mosmann
Jan 1, 1980·International Review of Cytology·A H WyllieA R Currie
Apr 1, 1994·Mayo Clinic Proceedings·H J Long
Sep 7, 1994·Journal of the National Cancer Institute·B W Stewart
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·D E SchteingartL L Wotring
Jan 1, 1996·Nature Medicine·A F WahlD A Galloway
Citations
Sep 27, 2001·World Journal of Surgery·H AhlmanS Lindstedt
Jan 1, 2000·Journal of Biomolecular Structure & Dynamics·G BischoffS Hoffmann
Jun 22, 2000·Cancer·T H WangY K Soong
Jun 12, 2002·Current Treatment Options in Oncology·R P Boushey, A P Dackiw
Jan 5, 2000·Nucleosides & Nucleotides·G BischoffS Hoffmann
Feb 25, 2010·Anesthesiology·Joseph F CottenDouglas E Raines
May 9, 2013·British Journal of Cancer·T UrupG Daugaard
Oct 7, 2019·Journal of Endocrinological Investigation·B RubinF Fallo
Feb 18, 2014·Endocrine-related Cancer·Constanze HantelFelix Beuschlein
Jul 24, 2013·Oncology Reports·Rui-Long XiaCai-Yun Fu
Mar 4, 2015·Environmental and Molecular Mutagenesis·Heng-Hong LiAlbert J Fornace
Jan 26, 2005·Endocrine Research·Mary H BassettWilliam E Rainey
Sep 20, 2019·Molecular and Cellular Endocrinology·Martina FragniSandra Sigala
Feb 28, 2001·Biochemical Pharmacology·D JunqueroA Delhon
Jun 28, 2001·Current Problems in Surgery·J A NortonH N Le
Nov 16, 2004·Molecular and Cellular Endocrinology·William E RaineyBernard P Schimmer
Sep 14, 2000·The Urologic Clinics of North America·L S Liou, R Kay
Mar 25, 2000·Endocrinology and Metabolism Clinics of North America·C A Stratakis, G P Chrousos